Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Antex Biologics (ANTX) -- Ignore unavailable to you. Want to Upgrade?

To: LPasko who wrote (724)	3/1/1998 6:42:00 PM
From: John R Resseger	Read Replies (1) \| Respond to of 1476

At this point Antex gets 100% of any Veterinarian applications of the vaccines + diagnostics and medicines for both humans and animals. SkB gets to share in the Human vaccines only. Leslie posted this <<The headline is also of significance. $200-$400 million/year in revenue. That is beyond my expectations used to value Antex. Remember the Antex is virtually guaranteed immediate sales to the US DoD .... and then has the largest worldwide sales and marketing force working with them. {{{{ The valuation rises to $6.52 on a fully diluted basis once Antex enters Phase III trials. }}} That includes ALL outstanding options>> -I find your valuation particularly interesting when you mention entering Phase lll trials...... -Let us not forget ANTX could market this vaccine before completion of Phase lll... OVERSEAS...as requirements are different over there....perhaps that is an additional reason we have picked up our new VP in charge of product development....just a thought... :)